Nuvectra (NVTR) Downgraded to Sell at ValuEngine
ValuEngine downgraded shares of Nuvectra (NASDAQ:NVTR) from a hold rating to a sell rating in a research report sent to investors on Friday.
Separately, Piper Jaffray Companies reissued a hold rating and set a $12.00 target price on shares of Nuvectra in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. Nuvectra presently has an average rating of Hold and a consensus price target of $12.00.
Nuvectra (NVTR) traded down $0.20 during trading hours on Friday, reaching $8.86. 26,500 shares of the company’s stock traded hands, compared to its average volume of 57,717. Nuvectra has a 12 month low of $4.90 and a 12 month high of $15.00. The company has a current ratio of 2.90, a quick ratio of 2.72 and a debt-to-equity ratio of 0.37.
Several hedge funds have recently added to or reduced their stakes in NVTR. Hodges Capital Management Inc. boosted its holdings in shares of Nuvectra by 18.6% in the 2nd quarter. Hodges Capital Management Inc. now owns 227,807 shares of the company’s stock valued at $3,025,000 after acquiring an additional 35,706 shares during the last quarter. Gilder Gagnon Howe & Co. LLC boosted its holdings in shares of Nuvectra by 12.5% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 953,431 shares of the company’s stock valued at $12,662,000 after acquiring an additional 105,580 shares during the last quarter. Gamco Investors INC. ET AL boosted its holdings in shares of Nuvectra by 4.2% in the 2nd quarter. Gamco Investors INC. ET AL now owns 35,194 shares of the company’s stock valued at $467,000 after acquiring an additional 1,434 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Nuvectra by 1.3% in the 2nd quarter. Wells Fargo & Company MN now owns 114,492 shares of the company’s stock valued at $1,520,000 after acquiring an additional 1,495 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Nuvectra by 1.7% in the 2nd quarter. Northern Trust Corp now owns 169,659 shares of the company’s stock valued at $2,253,000 after acquiring an additional 2,811 shares during the last quarter. 58.89% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/12/05/nuvectra-nvtr-downgraded-to-sell-at-valuengine.html.
Nuvectra Company Profile
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Stock Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related stocks with our FREE daily email newsletter.